Petros Includes Nitrate Patients In OTC ED Drug Self-Selection Studies
Executive Summary
Firms also notes in its announcement that FDA typically requires actual use trials for switch NDAs in addition to label comprehension studies, which it has conducted, and self-selection studies.
You may also be interested in...
Petros Pharma Introduces AI As ACNU Option In Research For OTC Switch Of Stendra ED Drug
Petros is first to introduce an OTC switch labeling tool which could be the next obvious step hiding in plain sight – AI, which wasn’t noted in FDA’s ACNU proposal and hasn’t previously been linked to a switch.
US FDA's ACNU Proposed Rule Played Petros Pharma’s Tune To Attempt OTC Switch Of ED Drug
For ED products, “where you have a contraindication for current use of nitrates, this enables you now to leverage technology to help assist the consumer without a physician intermediary to appropriately self-select. Yes, music to our ears, we loved it,” says president Fady Boctor.
Petros Plots Next Point On OTC ED Switch Path: Stendra Self-Selection Study
Two weeks after announcing strong results from label comprehension study, initiating self-selection study using Drug Facts label tested for nonprescription sales of its ED drug Stendra.